RxSight vs STAAR Surgical
RXST and STAA side by side, both in measuring, analyzing, and controlling instruments; photographic, medical and optical goods; watches and clocks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RXST and STAA compare
STAAR Surgical is the larger company, worth 6.0 times as much as RxSight ($1.3B against $224M).
STAAR Surgical grew revenue faster over the last twelve months (42.4% versus −13.2% for RxSight).
STAAR Surgical keeps more of each dollar of sales as profit, with a net margin of 0.16% compared with −36.8% at RxSight.
RxSight scores higher on the StockData Score (10 against 8 for STAAR Surgical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RXST | STAA |
|---|---|---|
| Size and price | ||
| Market cap | $224M | $1.3B |
| Share price | $5.38 | $26.78 |
| Change, 1 year | −47.4% | −2.3% |
| Change, 5 years | −60.2% | −75.7% |
| Beta (5Y) | 1.12 | 1.48 |
| Employees | 461 | 957 |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× (better) | 4.1× |
| P/B | 0.8× (better) | 3.6× |
| EV/EBITDA | – | 1621× |
| P/FCF | – | 75.2× |
| FCF yield | −12.1% | 1.3% (better) |
| Fair value | $20.63 | – |
| Margin of safety | 73.9% | – |
| Growth | ||
| Revenue growth (TTM) | −13.2% | 42.4% (better) |
| Revenue growth, 5Y average | 55.7% (better) | 7.9% |
| Profitability | ||
| Gross margin | 77.5% (better) | 73.6% |
| Operating margin | −43.2% | 0.21% (better) |
| Net margin | −36.8% | 0.16% (better) |
| FCF margin | −21.3% | 5.4% (better) |
| Return on equity | −17.3% | 0.15% (better) |
| Return on invested capital | −82.9% | 0.21% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −3674.3× | – |
| Current ratio | 4.07 | 4.68 (better) |
| Altman Z-score | −0.55 | 8.39 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.89% | – |
| Shareholder yield | −0.89% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 99.6% | 110% |
| Held by insiders | 5.4% | – |
| Insider net buying, 12 months | −$118K | $21.7M (better) |
| Short interest, % of float | 9.2% | – |
Go deeper
- RXST stock overview
- RXST income statement
- RXST valuation and score
- STAA stock overview
- STAA income statement
- STAA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.